#USA #New York #Pomerantz LLP #Valneva SE #IXCHIQ

Pomerantz Law Firm Investigates Claims on Behalf of Valneva SE Investors

In a recent announcement, the Pomerantz Law Firm has initiated an investigation aimed at uncovering potential claims from investors of Valneva SE, a company listed on NASDAQ under the ticker symbol VALN. This investigation comes on the heels of serious concerns regarding the company’s business practices and whether it or its executives may have engaged in securities fraud.

Background on Valneva SE

Valneva SE is a biotechnology company focused on developing and commercializing innovative vaccines for infectious diseases. One of its notable products is IXCHIQ, which is designed to protect against the chikungunya virus, a mosquito-borne illness that can lead to fever and debilitating joint pain. The company's trajectory has garnered significant attention in the investor community, particularly due to its advancements in vaccine technology.

Recent Developments Raising Red Flags

The impetus for the investigation stems from a troubling announcement made by the U.S. Centers for Disease Control and Prevention (CDC) on February 25, 2025. The CDC reported that it was investigating five cases of hospitalizations due to cardiac or neurological events in individuals aged 65 and above after being vaccinated with IXCHIQ. This news came as a shock not only to the general public but especially to Valneva investors, who began to worry about the implications of potential vaccine safety issues.

In the wake of the CDC's announcement, Valneva's American Depositary Receipt (ADR) experienced a significant drop in value, plummeting $1.06 per share—or 13.57%—over the following four trading sessions, culminating at $6.75 per ADR on February 28, 2025. Such a dramatic shift in market sentiment, triggered by safety concerns, often highlights the delicate balance biotech companies must maintain between public health and investor assurance, and many investors felt blindsided by the news.

FDA Involvement and Further Price Impact

The situation escalated further when, on August 22, 2025, the U.S. Food and Drug Administration (FDA) suspended the marketing application for IXCHIQ due to ongoing safety evaluations. This decision was another severe blow to Valneva's market presence, resulting in its ADR price falling an additional $2.21—or 18.99%—to close at $9.43 per ADR on August 25, 2025. With each piece of negative news, investor confidence waned, contributing to a volatile stock performance that underscored the risks associated with investing in biopharmaceutical companies.

Pomerantz’s Role and Legal Grounds for Investigation

As a firm recognized for its commitment to investor protection, Pomerantz LLP has established itself as a leader in representing victims of securities fraud and corporate misconduct. Founded by Abraham L. Pomerantz, the firm has nearly a century-long legacy of fighting for shareholders' rights, recovering billions in damages for class members affected by fraud. Their ongoing investigation into Valneva seeks to identify whether any unlawful activities may have led to the drop in stock price and investor losses.

Danielle Peyton of Pomerantz is the key contact for impacted investors. She strongly encourages anyone with claims or concerns about Valneva to reach out, ensuring that their voices are heard.

In conclusion, the actions of Valneva and its management through this significant period have come under scrutiny as the investigation progresses. Investors are understandably anxious as they await developments that may clarify the situation. With ongoing communications from both the CDC and FDA, as well as the active litigation environment spearheaded by Pomerantz, stakeholders will need to stay vigilant and prepared for whatever comes next. The hope remains that, through these investigations, transparency will prevail, and due accountability will be assured, allowing investors to reassess their positions moving forward.

For further inquiries, interested parties can contact Pomerantz LLP at 646-581-9980, ext. 7980.